Cytodyn Inc with Dr.Pourhassan gives an update on CytoDyn's COVID-19 path and more on Proactive Transcript
Very welcome back inside our Proactive newsroom. And joining me now is Nader Pourhassan, the CEO of CytoDyn. And Nader, good to have you back. How are you?
Doing great. Thank you, Steve, for having me.
Questions & Answers
Yeah. I want to ask you a little bit about your COVID-19 trial and when do you expect this to have an approval? I know there's a process that has to go through that.
So when we had DSMC, data safety monitoring committee look at the data on blinded, we did not accept the statistical penalty. So we don't see the data. And the reason we didn't do that is in the case we needed to increase the size of the trial and we had taken the statistical penalty, then we wouldn't be able to do that and that would have potentially harmed us.
So when DSMC came back and said to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
